Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CDW Holding ( (SG:BXE) ) just unveiled an update.
CDW Holding Limited’s subsidiary, ABio, in collaboration with Neoregen Biotech Co., Ltd., is advancing its research on next-generation Lipid Nanoparticle (LNP) technology. Following promising results from the in vitro phase, the joint research is set to enter the in vivo phase in April 2025, marking a significant step towards developing more effective and safer drug delivery systems. This progression is expected to enhance CDW’s position in the biotechnology industry, potentially benefiting stakeholders by expanding applications in mRNA vaccines, cancer treatment, and gene therapy.
More about CDW Holding
CDW Holding Limited is a company listed on the SGX Mainboard, operating in the biotechnology sector through its subsidiary A Biotech Co., Limited (ABio). The company focuses on the development of innovative technologies such as Lipid Nanoparticle (LNP) technology, which is crucial for drug delivery systems, mRNA vaccines, cancer treatment, and gene therapy.
YTD Price Performance: -7.00%
Technical Sentiment Signal: Buy
Current Market Cap: $21.5M
For a thorough assessment of BXE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts